ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.

Yun, M R; Choi, H M; Kang, H N; Lee, Yw; Joo, H-S; Kim, D H; Kim, H R; Hong, M H; Yoon, S O; Cho, B C

Yun, M R; Choi, H M; Kang, H N; Lee, Yw; Joo, H-S; Kim, D H; Kim, H R; Hong, M H; Yoon, S O; Cho, B C.

Affiliation

Yun MR; JEUK Institute for Cancer Research, JEUK Co., Ltd., Gumi-City, Kyungbuk, Republic of Korea.
Choi HM; Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kang HN; Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Lee Y; JEUK Institute for Cancer Research, JEUK Co., Ltd., Gumi-City, Kyungbuk, Republic of Korea.
Joo HS; Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim DH; Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim HR; JEUK Institute for Cancer Research, JEUK Co., Ltd., Gumi-City, Kyungbuk, Republic of Korea.
Hong MH; JEUK Institute for Cancer Research, JEUK Co., Ltd., Gumi-City, Kyungbuk, Republic of Korea.
Yoon SO; Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Cho BC; Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.

Oncogene ; 37(3): 377-388, 2018 01 18.

Article in En | MEDLINE | ID: mdl-28945228

Subject(s)

Aminopyridines/pharmacology; Antineoplastic Combined Chemotherapy Protocols/pharmacology; Carcinoma, Squamous Cell/drug therapy; Drug Resistance, Neoplasm; Head and Neck Neoplasms/drug therapy; Interleukin-6/metabolism; Morpholines/pharmacology; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors/pharmacology; Aminopyridines/therapeutic use; Animals; Antibodies, Monoclonal, Humanized/pharmacology; Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Autocrine Communication/drug effects; Carcinoma, Squamous Cell/pathology; Cell Line, Tumor; Cell Proliferation/drug effects; Extracellular Signal-Regulated MAP Kinases/metabolism; Female; Head and Neck Neoplasms/pathology; Humans; Interleukin-6/genetics; MAP Kinase Signaling System/drug effects; Mice; Mice, Inbred NOD; Morpholines/therapeutic use; Phosphatidylinositol 3-Kinases/metabolism; Protein Kinase Inhibitors/therapeutic use; Pyridones/pharmacology; Pyridones/therapeutic use; Pyrimidinones/pharmacology; Pyrimidinones/therapeutic use; RNA, Small Interfering/metabolism; Receptors, Interleukin-6/antagonists & inhibitors; Receptors, Interleukin-6/metabolism; STAT3 Transcription Factor/metabolism; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Antineoplastic Combined Chemotherapy Protocols / Morpholines / Interleukin-6 / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Phosphoinositide-3 Kinase Inhibitors / Head and Neck Neoplasms / Aminopyridines Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Oncogene Year: 2018 Document type: Article

Fulltext

XML

PubMed Links

Search on Google